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Abstract
The rapid proliferation of antibiotic-resistant pathogens has spurred the use of drug combinations to maintain clinical
efficacy and combat the evolution of resistance. Drug pairs can interact synergistically or antagonistically, yielding inhibitory
effects larger or smaller than expected from the drugs’ individual potencies. Clinical strategies often favor synergistic
interactions because they maximize the rate at which the infection is cleared from an individual, but it is unclear how such
interactions affect the evolution of multi-drug resistance. We used a mathematical model of in vivo infection dynamics to
determine the optimal treatment strategy for preventing the evolution of multi-drug resistance. We found that synergy has
two conflicting effects: it clears the infection faster and thereby decreases the time during which resistant mutants can arise,
but increases the selective advantage of these mutants over wild-type cells. When competition for resources is weak, the
former effect is dominant and greater synergy more effectively prevents multi-drug resistance. However, under conditions
of strong resource competition, a tradeoff emerges in which greater synergy increases the rate of infection clearance, but
also increases the risk of multi-drug resistance. This tradeoff breaks down at a critical level of drug interaction, above which
greater synergy has no effect on infection clearance, but still increases the risk of multi-drug resistance. These results
suggest that the optimal strategy for suppressing multi-drug resistance is not always to maximize synergy, and that in some
cases drug antagonism, despite its weaker efficacy, may better suppress the evolution of multi-drug resistance.
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Introduction
As antibiotic-resistant pathogens become more common,
clinicians increasingly turn to multi-drug treatment to control
infection [1–5]. The inhibitory effect of two drugs in combination
can be larger or smaller than expected from their individual
effects, corresponding to synergistic or antagonistic interactions
between the drugs respectively [6–9]. Synergistic interactions are
usually thought of as advantageous since, for a given amount of
drug, they more effectively inhibit the growth of drug-sensitive
pathogens. However, in vitro studies have suggested that, for the
same level of inhibition, more synergistic drug pairs may foster
antibiotic resistance [10–12]. Antagonistic drug combinations, on
the other hand, are less effective at inhibiting drug-sensitive
pathogens, but can reduce and even invert the selective advantage
of single-drug resistant mutants, causing selection against resis-
tance [13].
These recent observations point to a possible tradeoff in the
choice of synergistic versus antagonistic drug combinations with
respect to their effects on treating infection and suppressing
antibiotic resistance. However, while antagonistic drug combina-
tions increase selection against resistance, and should therefore
minimize resistance, they also kill the infection more slowly, giving
resistance more time to emerge. Antagonism therefore has two
contradicting effects on the evolution of resistance: on one hand, it
increases the risk of resistance by decreasing antibiotic inhibition
and allowing more time for resistance to evolve; on the other hand,
it decreases the risk of resistance by decreasing the selective
advantage of single drug resistant mutants. We ask which of these
opposing effects is stronger, and therefore which type of drug
interaction – synergistic or antagonistic – best prevents the overall
chance of emergence of multi-drug resistance.
We frame this problem in the context of a clinical infection,
formalizing the two main factors in the success of an antibiotic
treatment as ‘‘treatment efficacy’’ and ‘‘prevention of multi-drug
resistance.’’ Treatment efficacy is the rate at which the infection is
cleared by the treatment, and can be defined as the reciprocal of
the time, tclear, at which the total infection is eliminated, 1=tclear.
Prevention of multi-drug resistance is defined as the reciprocal of
the number of double-drug resistant mutants expected to arise
during the course of treatment, 1=Ndouble. In real infections, multi-
drug resistance can arise either through a single mutation
conferring cross-resistance to both drugs simultaneously, or
through the sequential acquisition of mutations conferring
resistance to each drug individually [10,14–16]. Furthermore,
resistance to a single drug can develop in several small steps or in
one large step [15,17–19]. For simplicity, and to emphasize the
role of drug interactions, we concentrate here on an idealized case
in which resistance to the two-drug combination evolves through
sequential acquisition of two spontaneous mutations, each
conferring strong resistance specific to one of the two antibiotics
(Fig. 1).
We asked what level of drug interaction (ranging from strong
synergy to strong antagonism) maximizes treatment efficacy
(1=tclear) and prevention of multi-drug resistance (1=Ndouble).
Maximizing 1=tclear is straightforward: as more synergistic drug
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quickly, maximally synergistic drug pairs should maximize 1=tclear
[4,20]. In attempting to maximize 1=Ndouble, however, the best
choice of drug interaction is less clear. Assuming sequential
acquisition of resistance to each drug, the rate at which multi-drug
resistance arises will depend on the size of the single-drug resistant
mutant population. The size of this single-mutant population, in
turn, depends on two factors: the rate at which such mutants arise,
and their selective advantage over the wild-type. Synergistic drug
pairs decrease the first factor because they more quickly kill the
source wild-type population from which single mutants arise.
However, synergistic drug pairs also increase the second factor:
single-drug resistant mutants will have a strong selective advantage
in a synergistic treatment because resistance removes both the
burden of one drug, and its enhancing effect on the other drug
[13] (Fig. 1B). Synergistic drug pairs therefore decrease the rate at
which single-drug resistant mutants appear, but increase their
selective advantage. Antagonistic drug pairs do the opposite:
though they allow a larger number of single-drug resistant mutants
to arise, they also diminish the selective advantage of these
mutants. The net effect of a given drug interaction on the
evolution of multi-drug resistance is therefore not obvious, and
requires a quantitative model to determine the overall impact of
mutation and selection’s countervailing effects.
To better understand how drug interactions affect the risk of
multi-drug resistance, we used a population genetic model of
microbial infection previously applied to predict single-drug
resistance in vivo in mice [21], and modified it to account for the
sequential acquisition of mutations leading to multi-drug resis-
tance. We used this model to ask what level of drug interaction
maximizes treatment efficacy (1=tclear) and prevention of multi-
drug resistance (1=Ndouble).
Results
Simple model for the evolution of resistance in multi-
drug treatment
We based our model on work by Jumbe et al. [21], which
investigated a mouse-thigh P. aeruginosa infection model [22–24]
and provided a mathematical model that quantitatively described
the relationship between exposure to the fluoroquinolone
antibiotic levofloxacin, and changes in drug-susceptible and
drug-resistant bacterial subpopulations over time. This mathemat-
ical model was successful both in reproducing the observed
changes in drug-susceptible and –resistant subpopulations over
time, and in predicting the dose of levofloxacin needed to suppress
amplification of levofloxacin-resistant (efflux-pump-expressing)
mutants. To investigate the effect of antibiotic interactions on
Figure 1. Model of the evolution of resistance in synergistic
and antagonistic drug treatments. (A) Graphical representation of
model ODEs describing three bacterial subpopulations: the wild-type
sensitive to both drugs (black, Eq. 1), single-drug resistant mutants
(blue, Eq. 2), and double-drug resistant mutants (red, Eq. 3). Wild-type
and single-drug resistant subpopulations grow with rate G (Eq. 4),
mutate with rate mG and die with antibiotic killing rates K ~ D DWT

and
K ~ D Dsingle

, where ~ D DWT and ~ D Dsingle are the effective drug doses they
experience, respectively (Eq. 5). We do not model the growth of the
double-drug resistant strain, but simply follow the number of such
mutants expected to arise via mutation. (B) The wild-type, single-drug
resistant and double-drug resistant mutants experience different
effective doses, ~ D D, in the multi-drug treatment. The wild-type (black
bars) is affected by both the drugs and their interaction, yielding
~ D DWT~D 2ze ðÞ , where D is the dose of each of the drugs A and B (we
assume the two drugs are given at the same dose) and e is the level of
their interaction (ew0, synergistic; e~0, additive; ew0, antagonistic).
We assume strong resistance, such that resistant mutants are
completely unaffected by the drug to which they are resistant; the
effective drug dose felt by the single-drug resistant mutant is therefore
that of one of the drugs alone, ~ D Dsingle~D, and is independent of e (blue
bars have a fixed value). Because double-drug resistant mutants are
fully resistant to both antibiotics, they feel an effective dose of 0 (red
bars). Increased synergy therefore increases killing of the wild-type, but
also increases the selective advantage of the single-drug resistant
mutants. Antagonistic drug pairs reduce this selective advantage, and
can completely eliminate (e~{1) or even invert it (ev{1).
doi:10.1371/journal.pcbi.1000796.g001
Author Summary
The use of antibiotics against bacterial infections has led to
the emergence of multi-drug resistant pathogens such as
tuberculosis and MRSA. In order to control resistance,
clinicians have increasingly turned to multi-antibiotic
therapies. The common wisdom is to use combinations
of drugs that act synergistically to kill the infection, but the
impact of drug synergy on the evolution of resistance is
unclear. Using mathematical simulations of an in vivo
infection model, we asked what level of drug synergy
would minimize the risk of multi-drug resistance while
preserving the efficacy of treatment. We found that
synergy may increase or decrease the risk of multi-drug
resistance in a given treatment, depending on infection
properties such as mutation rate and the availability of
resources. Surprisingly, under conditions of strong com-
petition for resources within the host, we found that
maximal synergy—currently favored in clinical settings—
can actually increase the risk of multi-drug resistance. Our
results identify conditions under which drug synergy
exacerbates the problem of multi-drug resistance, and
offer guidelines for the selection of drug pairs that
suppress it.
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simple scenario, we modified the Jumbe et al. model in four ways:
we include a second antibiotic in our model; we assume a constant
antibiotic dose; we assume a low hill coefficient, consistent with the
mechanisms of a range of antibiotics [25]; and we assume no cost
for antibiotic resistance. The consequences of these assumptions
are discussed throughout the text.
Our model incorporates treatment with two antibiotics, A and
B. It uses a set of ordinary differential equations (ODEs) to follow
the population sizes of the drug-sensitive wild-type strain (NWT),
the total single-drug resistant population (Nsingle~NARzNBR;w e
assume symmetry between drugs A and B such that their
respective resistant populations are equal, NAR~NBR), and the
expected number of multi-drug resistant mutants (Ndouble) arising
over time (Fig. 1A; Methods):
_ N NWT~NWT G{K ~ D DWT
 
{2mGNWT ð1Þ
_ N Nsingle~Nsingle G{K ~ D Dsingle
 
z2mGNWT{mGNsingle ð2Þ
_ N Ndouble~mGNsingle ð3Þ
Populations are affected by growth, antibiotic killing and
mutation, where G, K and m are the growth rate, antibiotic
killing rate and frequency of resistance mutations per generation,
respectively, and ~ D DWT and ~ D Dsingle are the effective doses of
antibiotic felt by the wild-type and single-drug resistant mutant
populations. We assume for simplicity that antibiotic resistance
imposes no fitness cost, so that the growth rates of the sensitive and
resistant populations are the same. To account for competition for
resources, we assume this growth rate is given by the logistic
equation,
G~g 1{
Ntot
Nmax

, ð4Þ
where g is the maximal growth rate, Ntot~NWTzNsingle is the
total population size, and Nmax is the maximal carrying
capacity (Fig. S1B). This competition for resources was
included in the in vivo murine infection model [21], and has
been observed in or inferred from a range of infections [26],
including S. pneumoniae [27], and Methicillin-Resistant S. aureus
(MRSA) [28].
While we assume the growth rates of the wild-type and single-
drug resistant mutants are the same, the rates K at which they are
killed by antibiotic are different and depend on the effective
antibiotic dose, ~ D D, felt by each population:
K ~ D D

~
k
1z~ D D{H ð5Þ
where k is the maximal killing rate and H is the Hill coefficient,
which determines the steepness of the killing rate as a function of
drug dose. In contrast to Jumbe et al., we set H~1, which is
representative of many common antibiotics [25], although
different values of H give rise to similar overall model behavior
(Fig. S2). The effective drug dose, ~ D D, depends on the dosage of the
two drugs and on their interaction (Fig. 1B, Text S1, Fig. S1A).
For simplicity we assume both drugs are administered at the same
dose, D, defined in units of their minimum inhibitory concentra-
tion (MIC), the single-drug dose at which the wild-type death rate
equals its growth rate at resource-unlimited conditions:
DMIC~
k
g
{1
 {1=H
. For the wild-type, the effective dose is
the sum of the dosage of the two drugs plus their level of
interaction e: ~ D DWT~ 2ze ðÞ D. Values of e are positive, zero, or
negative for synergy, additivity and antagonism, respectively.
While in practice the value of e is specific to a given drug pair [29],
we treat it as continuous in order to investigate all potential
treatment strategies. We assume that single-drug resistant mutants
are affected by only one of the drugs, which is reasonable in the
case of resistance mechanisms that decrease the intracellular
concentration of antibiotic, such as efflux pump expression or
enzymatic degradation [11,13,30]. The effective dose of single-
drug resistant mutants is therefore ~ D Dsingle~D, and is independent
of e (Fig. 1B). Except where indicated, we set D~7 MIC (general
model behavior is robust to changes in drug dosage, Fig. S2A),
which for an additive drug pair is consistent with the drug dosage
used in Jumbe et al. [21].
Mutations from wild-type to single-drug resistance, or from
single- to double-drug resistance, arise at a rate m per individual
per replication, or mG per individual per unit time. Since in any
effective treatment the number of double mutants arising is smaller
than 1, we do not account for the growth or death of this fractional
population, but rather define Ndouble as the integrated number of
double mutants generated via mutation during treatment (Eq. 3).
Prevention of multi-drug resistance is then defined as 1=Ndouble.
The model therefore consists of Eqs. 1–5. Parameter values,
following Jumbe et al. [21], are given in Table S1. Initial conditions
for the model are N0
WT, N0
single, N0
double - the population sizes at the
onset of treatment. We assume that prior to treatment, the infections
have grown from a single cell to the initial population size N0
tot while
mutating; while the overall mutation rate is a function of model
parameters m, g and Nmax (Eqs. 2, 3), N0
single and N0
WT are functions
of m alone: N0
single~2mN0
tot, N0
WT~ 1{2m ðÞ N0
tot. No double-
drug resistant mutants are present: N0
double~0. We integrate the
ODEs with these initial conditions (Methods) and define tclear as the
time at which the total population size drops below one (tclear is
defined as infinity if the population reaches a non-zero steady state).
Antibiotic interactions create a saturable tradeoff
between treatment efficacy and prevention of multi-drug
resistance
To determine the impact of drug interaction on treatment
outcome, we first looked at the differences in treatment efficacy
(1=tclear) and prevention of multi-drug resistance (1=Ndouble)o v e ra
range of drug interaction values (e~{1:5t o1 :5) whileholding drug
dosage fixed (Fig. 2, D~7 MIC). We observed two distinct and
robust (Fig. S2) behaviors, depending on whether e falls above or
below a critical value, e  ( F i g .2 ;f o rt h ep a r a m e t e r su s e d ,e &0:14).
For eve , we observed a tradeoff between treatment efficacy and
prevention of resistance. In this regime, increasing synergy yields
greater 1=tclear (Fig. 2, unshaded region); this is expected, as
increasing the synergistic interaction between the drugs kills the
wild-type more quickly. Despite faster infection clearance, however,
greater synergy actually decreases 1=Ndouble; namely, it increases the
risk of multi-drug resistance. Conversely, more antagonistic drug
pairs increase 1=Ndouble, albeit at the expense of reduced efficacy.
This tradeoff between efficacy and prevention of resistance
breaks down at a critical threshold, e , above which increasing
synergy no longer increases 1=tclear, but still decreases 1=Ndouble
(Fig. 2, shaded region). Above this ‘‘synergy ceiling,’’ further
increasing synergy therefore has only undesirable effects, since it
Optimal Antibiotic Synergy
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efficacy. Optimal drug pairs for treating the given infection must
therefore have a level of drug interaction lower than e  and, due to
the tradeoff between 1=tclear and 1=Ndouble, the optimal value of e
will depend on the relative importance assigned to these two
conflicting goals.
The frequency of resistance mutations determines the
‘‘synergy ceiling’’ e 
To understand what determines the level of the synergy ceiling,
e , we asked what causes the transition from tradeoff behavior at
eve , to plateau behavior at ewe  (Fig. 2). Due to the sharp
biphasic behavior of efficacy (1=tclear) around e , we looked to
population time courses to determine how the time of clearance,
tclear, was affected by drug interactions below, at or above e 
(e~{1:5,0:14,1:5, respectively; Fig. 3A). For eve  (Fig. 3A, top),
the wild-type subpopulation outlives the single-drug resistant
mutants and tclear~tWT
clear. Since wild-type killing is stronger for
more synergistic drug pairs, increasing e decreases tWT
clear, explaining
why efficacy increases with e in this region (Fig. 2, unshaded region).
For ewe  (Fig. 3A; bottom), however, the wild-type is eliminated
before the single-mutant population, and tclear~t
single
clear . Because the
killing rate of the single-drug resistant mutants is independent of e,
t
single
clear is effectively independent of e, causing 1=tclear to plateau for
ewe  (Fig. 2, shaded region). e  is therefore the level of drug
interaction for which wild-type and single-mutant populations are
cleared simultaneously (tWT
clear~t
single
clear ; Fig. 3A, middle).
Since e  represents the level of drug interaction for which
tWT
clear~t
single
clear , parameters that differentially alter tWT
clear and t
single
clear will
alter e . While we found that a number of model parameters had
some effect on e  (Fig. S2), the strongest effect was due to changes
in the frequency of resistance mutations, m. m differentially affects
tWT
clear and t
single
clear because, although it has virtually no effect on tWT
clear,
the single-mutant population size at the onset of treatment
increases linearly with m, N0
single~2mN0
tot, thereby increasing
t
single
clear . For tWT
clear to match this increase in t
single
clear , the wild-type
killing rate must decrease; namely, e  must be reduced. We
therefore expected e  to decrease with increasing m and, indeed,
increasing the frequency of resistance mutations gave rise to
consistent decreases in e  (Fig. 3B). Interestingly, for high
frequencies of resistance (mw2|10{6) the synergy ceiling e  falls
below zero (representing an antagonistic drug interaction); in this
case mildly synergistic and even additive interactions fall in the
undesirable regime where the risk of multi-drug resistance
increases without any corresponding gain in treatment efficacy.
Competition for resources underlies the tradeoff
between treatment efficacy and prevention of multi-drug
resistance
Why does synergy, despite clearing the infection faster, increase
the risk of multi-drug resistance (Fig. 2)? Since synergistic drug pairs
clear the infection more quickly than antagonistic drug pairs,
the rate at which they generate double mutants must also be
higher. The overall rate at which double mutants arise,
_ N Ndouble~mGNsingle~mgNsingle 1{
Ntot
Nmax

(Eqs. 3, 4), is affected
by two variables: it increases with the size of the single-mutant
population, Nsingle, and decreases with total population size, Ntot,
due to the inhibitory effect of resource limitation on growth and
mutation (Fig. 4A). The total numberof doublemutants expected to
arise is simply the integral of this instantaneous rate over the
treatment course. In order to determine why synergistic treatments
increase _ N Ndouble, we therefore analyzed the trajectories of synergistic
and antagonistic treatments through the space of Nsingle versus Ntot
(Fig. 4A; e~1:5, solid line, e~{1:5, dashed line). The initial slopes
of these trajectories (Fig. 4A, arrows) are determined by the relative
fitness of the wild-type and single-drug resistant populations under
antibiotic treatment. The synergistic treatment selects strongly
against the wild-type population, producing a trajectory with a steep
slope that drives treatment intoa region of high _ N Ndouble (Fig. 4A, red
region); this is because the rapid decrease in wild-type population
size relieves competition for resources, creating a window of
opportunity in which the still-large single-mutant population can
rapidly grow and mutate. Conversely, the antagonistic treatment
selects only weakly against the wild-type, producing a trajectory
with a shallow slope that skirts the high _ N Ndouble region. Antagonistic
drug pairs therefore decrease _ N Ndouble in a competition-dependent
fashion: weak killing of the wild-type maintains competition for
resources, limiting growth and mutation of the single-drug resistant
population until it is eliminated.
Itisimportanttonotethatresourcecompetitionissignificantonly
at the beginning of treatment, when Ntot&Nmax. If competition for
resources is required for the advantage of antagonism over synergy
in preventing resistance, then we should expect a decrease in initial
population size to decrease this advantage. To test this prediction,
we looked at the relative ability of our representative synergistic
(e~1:5) and antagonistic (e~{1:5) drug pairs to prevent multi-
drug resistance, tant
clear=t
syn
clear, over a range of N0
tot (Fig. 4C, circles;
sensitivity to other model parameters is minimal, Fig. S2). Indeed,
we found that the advantage of antagonistic drug pairs in prevent-
ing resistance (tant
clear=t
syn
clearv1, below dashed line) was limited to
cases where N0
tot is close to Nmax. In fact, for N0
tot significantly lower
than Nmax, the trend reverses and synergy better prevents resistance
(tant
clear

t
syn
clearw1, above dashed line). This is because, for low
population sizes, resource competition effects are negligible;
_ N Ndouble therefore no longer depends on Ntot, and becomes a
Figure 2. Choice of drug interaction presents a tradeoff
between treatment efficacy and prevention of multi-drug
resistance. Below a critical level of drug interaction (unshaded region,
eve ), treatment efficacy (1=tclear, blue) and prevention of multi-drug
resistance (1=Ndouble, black) exhibit a tradeoff: increased synergy yields
higher efficacy, but at the expense of lower resistance prevention.
Above e , however, efficacy plateaus: increasing synergy beyond this
‘synergy ceiling’ fails to improve treatment efficacy, but continues to
diminish resistance prevention (shaded region, ewe ).
doi:10.1371/journal.pcbi.1000796.g002
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Nsingle by quickly killing the wild-type population from which single
mutants arise, they therefore also better limit multi-drug resistance
in cases of weak competition. Indeed, this advantage of synergy
disappeared entirely when we artificially turned off wild-type to
single-mutant mutation, allowing only those single mutants present
at the start of treatment to contribute to _ N Ndouble (Fig. 4C, triangles).
Importantly, when competition for resources is weak (N0
tot
significantly less than Nmax, tant
clearwt
syn
clear), the tradeoff between
treatment efficacy and prevention of multi-drug resistance no
longer exists (Fig. 4D; compare with Fig. 2). As a result, e  is no
longer useful as a ‘‘synergy ceiling’’ because, although drug pairs
with ewe  do not further improve 1=tclear, they do improve
1=Ndouble. For infections with weak competition, the use of
maximally synergistic drug pairs therefore represents the best
possible treatment strategy.
Discussion
We used a population dynamic model of bacterial infection to
determine what drug interactions best suppress the emergence of
multi-drug resistance. Whereas antagonistic drug pairs kill
bacterial populations more slowly, and therefore allow more time
for resistance to emerge, they also decrease the selective advantage
of resistant mutants. Which of these two opposing effects of
antagonism dominates in determining its overall impact on the
chance of evolving multi-drug resistance? Framing this problem in
the context of a clinical infection, we asked how two measures of
treatment outcome, treatment efficacy and prevention of multi-
drug resistance, depend on drug interaction.
We found that the optimal drug interaction can be determined
primarily as a function of two infection parameters: population
size at the outset of treatment, and the frequency of resistance
mutations (see summary of our results in Fig. S3). For clinically
relevant scenarios where initial population sizes are well below the
carrying capacity, competition for resources is weak and synergy,
which is typically preferred in clinical settings for its superior
treatment efficacy [3,4,20], is also expected to best prevent the
emergence of multi-drug resistance.
Where resource competition is significant, however, strong
synergy may not always be the optimal treatment strategy. Real
infections frequently exhibit competition, due either to a scarcity of
Figure 3. The synergy ceiling e  is determined by clearance of the wild-type population before the single-mutant subpopulation. (A)
Population sizes of the wild-type (NWT, black) and single-drug resistant mutants (Nsingle, blue) over treatment courses with levels of interaction
below, at or above the critical value e  (e~{1:5, 0:14, 1:5). Populations start with sizes N0
WT, N0
single and are killed by antibiotics until they are cleared
at times tWT
clear and t
single
clear respectively; the overall time of clearance of the infection is simply tclear~max tWT
clear, t
single
clear
	

(orange markers). The interaction
level e affects the order in which the wild-type and the single-drug resistant subpopulations are eliminated: below the synergy ceiling (eve , top), the
wild-type is eliminated after the single-drug resistant mutant and tclear~tWT
clear; at the synergy ceiling (e~e , middle), the two populations die
simultaneously and tclear~tWT
clear~t
single
clear ; above the synergy ceiling (ewe , bottom), the single-drug resistant mutant outlives the wild-type, such that
tclear~t
single
clear . Because increasing e increases the wild-type killing rate but has no effect on the single-mutant killing rate, efficacy increases with e
below the synergy ceiling (tclear~tWT
clear), but plateaus at and above it (tclear~t
single
clear ; vertical dashed line: notice that tclear~t
single
clear is the same both at and
above the synergy ceiling). (B) Increased mutation rates, m, give rise to lower e . Inset: treatment efficacy, 1=tclear, plateaus at lower levels of drug
interaction e for higher mutation rates (m~10{7, blue; m~10{6, orange; m~10{5, green; blue and green lines are shifted slightly along y-axis for
clarity); e  values for each line are indicated by vertical dashed lines, and by circles in the main panel. Orange markers indicate the treatment efficacy
achieved for different values of e when m~10{6, corresponding to the tclear values in panel A.
doi:10.1371/journal.pcbi.1000796.g003
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(e.g. in biofilm formation [33,34]). In our model, such competition
is predicted to give rise to a tradeoff between treatment efficacy
and resistance prevention: increased synergy leads to greater
efficacy, but at the expense of an increased risk of multi-drug
resistance. Importantly, this tradeoff saturates for levels of synergy
greater than a critical value e , above which greater synergy does
not further increase efficacy, but still increases the risk of multi-
drug resistance. If the goal is to minimize multi-drug resistance,
then choosing drug interactions above this ‘‘synergy ceiling’’ may
be counterproductive. This is especially important given the
dependence of e  on the frequency of resistance mutations: our
model predicts that for infections where resistance rates are high
(mw2|10{6) e  may be negative (antagonistic), favoring the use
of antagonistic drug pairs over mildly synergistic or even purely
additive antibiotic combinations. Indeed, for the modified Jumbe
Figure 4. Prevention of multi-drug resistance by drug antagonism depends on resource competition. (A) Heat map of instantaneous
rates of double-mutant formation, _ N Ndouble, as a function of single-mutant and total population sizes: _ N Ndouble increases with the size of the single-
mutant population, and decreases with total population size due to resource competition. Treatment course trajectories for synergistic (e~1:5, solid
line) and antagonistic (e~{1:5, dashed line) drug treatments begin with total initial population size N0
tot~Nmax and initial single-mutant population
size N0
single~2mNmax (magenta circle), and move toward the origin as the infection is cleared (black circles indicate 20-minute intervals). The different
initial slopes of these trajectories (arrows), determined by the relative fitness of the wild-type and single-drug resistant mutants in synergistic versus
antagonistic treatments, lead them to different regions of the heat map: synergistic drug pairs quickly kill the wild-type, relieving resource
competition before the single-mutant population is killed and leading to a region with high _ N Ndouble (solid trajectory goes through red region), while
antagonistic pairs kill the single mutants before competition is relieved, leading to a region of low _ N Ndouble (dashed trajectory goes through green
region). (B) The _ N Ndouble over each treatment plotted as a function of time; black circles indicate 40-minute intervals in this panel. (C) Relative ability of
these strongly synergistic and antagonistic drug pairs to prevent multi-drug resistance, tant
clear=t
syn
clear, for different initial population sizes (circles). For
strong resource competition at the start of treatment (N0
tot close to Nmax), antagonistic drug pairs prevent resistance better than synergistic drug
pairs (tant
clear=t
syn
clearv1). For weak competition, however (N0
tot significantly less than Nmax), synergistic drug pairs better prevent resistance
(tant
clear=t
syn
clearw1). Artificially turning off wild-type to single-drug resistant mutation during treatment (leaving only the single-mutant population that
exists at the onset of treatment) eliminates the advantage of synergy over antagonism at low N0
tot (triangles). (D) When initial population size is low
and synergy is advantageous, the tradeoff between treatment efficacy and prevention of multi-drug resistance is eliminated, such that maximally
synergistic drug pairs yield both the greatest treatment efficacy and greatest prevention of multi-drug resistance (compare panel C to Fig. 2).
doi:10.1371/journal.pcbi.1000796.g004
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resistance frequency we use may be an overestimate (Jumbe et al.
determined this as the rate of all mutations conferring only a 3-fold
increase in the MIC), these and higher mutation rates have been
identified in human pathogens [35,36]. Together, the potential for
strong competition and high mutation rates in infection suggest
that the tradeoff and synergy ceiling behaviors observed in our
model – as well as the ability of antagonistic drug pairs to
minimize multi-drug resistance – may describe the properties of
some clinical infections.
We emphasize that drawing concrete therapeutic conclusions
from this study would be beyond its scope. Our model
incorporates many simplifying assumptions: we assume e to be a
fixed value, although it has been observed to change with both the
absolute and relative doses of the antibiotics administered [37,38];
drug administration and pharmacokinetics are not considered,
although they may significantly impact the evolution of resistance
[23,39–42]; resistance mutation rates per generation are assumed
to be independent of growth and antibiotic-killing rates; and while
we consider an idealized case in which multi-drug resistance arises
from strong, sequential mutations conferring resistance to each
antibiotic, real mutations may confer cross-resistance to both drugs
simultaneously, or only partial resistance to a single drug
[10,14,16]. One consequence of partial resistance is antibiotic
killing of drug-resistant mutants for drug interactions above e ;
while for strong resistance this killing would be minimal, weak
resistance may allow enough killing to undermine synergy ceiling
behavior (Fig. S4). Finally, we note that this model does not
consider the impact of host immune defenses, which may
substantially impact microbial growth and death rates in clinical
infections [43,44]; whether the influence of host defenses favors
the use of some drug combinations over others, however, remains
to be seen.
While these caveats indicate the limitations of this simple model
and suggest important avenues for future study, our results make a
number of novel predictions about the relationship between drug
interaction and multi-drug resistance: that there exist conditions
under which antagonistic drug pairs may better prevent multi-
drug resistance despite their weaker efficacy; that there is a synergy
ceiling to how much efficacy can be achieved by modulating drug
interaction; and that, below this ceiling, changes in drug
interaction may produce a tradeoff between inhibition and
multi-drug resistance. By basing our model on a previous
experimental model of infection [21], we have identified regions
of parameter space in which such behaviors may be relevant in a
clinical scenario, and which could be tested in future experimental
models of infection. Finally, our model highlights the idea that the
optimal choice of drug pair in treating an infection may be
contextual: while strongly synergistic drug pairs seem the preferred
strategy in scenarios where resource limitation and other forms of
competition are negligible, antagonistic drug pairs may best
prevent resistance in cases of high mutation rates and strong intra-
infection competition. While present therapeutic knowledge
generally favors synergistic drug pairs, our work motivates further
research into the impact and potential utility of antagonistic
interactions both in clinical and in ecological settings.
Methods
Model details
Our model consists of 3 ODEs (Eq. 1–3) describing the
population sizes of the wild-type and single-drug resistant mutants
(NWT, NWT), as well as the number of double mutants expected to
arise during a treatment course (Ndouble). Parameter values for this
model include first-order maximal growth (g) and death rate (k)
constants, carrying capacity Nmax and mutation rate m (per
individual per generation), which were taken from the in vivo
murine model investigated in Jumbe et al. [21] (Table S1). Initial
population sizes (N0
WT, N0
single) were determined by assuming that,
prior to treatment, the infections grew from a single cell to the
initial population size N0
tot while mutating, such that
N0
single~2mN0
tot and N0
WT~ 1{2m ðÞ N0
tot; unless otherwise indicat-
ed, N0
tot~Nmax. ODEs were solved in MATLAB (Version 7.1,
MathWorks, Natick, MA) using a built-in, numerical ODE solver
(ODE45). To avoid artifacts associated with using continuous
ODEs to describe finite populations, each step was modified with
the assumption that the wild-type or single-drug resistant
population is eliminated (size decreases to zero) if its size drops
below one.
Supporting Information
Figure S1 Models of drug interaction and logistic growth. (A)
Model of drug interaction. The effective drug dose for the wild-
type strain, ~ D DWT, is a function of three variables: the doses of drugs
A and B (DA, DB) and the interaction parameter e (Text S1).
Isoboles of the wild-type effective dose (~ D DWT~1 MIC), are shown
for additive (e~0, black), synergistic (ew0, red) and antagonistic
(ev0, blue) drug pairs. While for additive drug pairs the effective
dose is a simple sum of the drugs’ individual doses, synergistic or
antagonistic drug pairs achieve the same effective dose with
smaller or larger drug doses, respectively. All model simulations
fall on the dashed line, where drug doses are equal: DA~DB. (B)
Logistic growth model. As the population size, Ntot, increases,
competition causes the growth rate, G, to fall from its maximal
value, g, to 0 at the carrying capacity, Nmax (Eq. 4). Unless
otherwise indicated, in model simulations Ntot~Nmax at the outset
of treatment (black circle).
Found at: doi:10.1371/journal.pcbi.1000796.s001 (0.11 MB TIF)
Figure S2 Prevention of resistance, and the synergy ceiling e ,
are robust to changes in model parameters. To test the robustness
of the model to parameter changes, we varied each parameter
independently and measured its effect on both the relative ability
of strongly synergistic and antagonistic drug pairs (e~1:5,{1:5)t o
prevent multi-drug resistance, ssyn=sant (solid black line), and the
level of the synergy ceiling e  (solid blue line). All lines have
undergone 5-point smoothing. Dashed lines indicate the points at
which synergistic and antagonistic drug pairs prevent resistance
equally well (ssyn=sant~1, black), or the synergy ceiling is additive
(e ~0, blue). In each panel, those points corresponding to the
original set of model parameters are indicated by circles. (A)
ssyn=sant and e  vary little with changes in drug dose D, (B)
carrying capacity Nmax, or (C) maximal growth rate g. (D) As
previously discussed, increases in the frequency of resistance
mutations m decrease e  substantially (Fig. 3), while having no
significant effect on ssyn=sant. (E) Likewise, increases in the initial
population size, N0
tot, significantly decrease ssyn=sant (Fig. 4), but
also decrease e . (F) Changes in the Hill coefficient, H,o f
antibiotic killing had a more complex effect on ssyn=sant and e :
while ssyn=sant was consistently less than 1 over a wide range of H
(antagonism better prevents resistance), its magnitude was
parabolic with H, with antagonistic drug pairs having the greatest
advantage for H&3. e  also appeared parabolic with H and was
lowest (most antagonistic) at H&2. In the limit of large H,
maximal antibiotic killing rates are achieved for both wild-type
and single-drug resistant populations, regardless of drug interac-
tion. Synergistic and antagonistic drug pairs therefore fail to
differentially impact wild-type killing rates, and ssyn=sant~1 at
Optimal Antibiotic Synergy
PLoS Computational Biology | www.ploscompbiol.org 7 June 2010 | Volume 6 | Issue 6 | e1000796high H (black line). Furthermore, saturation of killing rates causes
tWT
clear to be greater than t
single
clear for all values of e; e  is therefore
undefined for Hw3 (blue line), though saturation of the wild-type
killing rate still causes efficacy to effectively plateau for low values
of e.
Found at: doi:10.1371/journal.pcbi.1000796.s002 (0.37 MB TIF)
Figure S3 Optimal drug interactions as a function of resistance
frequency and initial population size. The contour map shows the
synergy ceiling, e , for a given combination of resistance mutation
frequency, m, and population size at the start of treatment, N0
tot. e 
decreases monotonically with increasing m (as in Fig. 3), but is
nearly unaffected by N0
tot. The black line is a single contour above
which antagonistic drug pairs prevent multi-drug resistance better
than synergistic drug pairs (ssyn=santv1). Above this contour,
greater synergy increases the chance of multi-drug resistance; the
optimal drug interaction must therefore fall below e , with its
specific value depending on the priority assigned to treatment
efficacy versus prevention of multi-drug resistance. Below the
contour, however (ssyn=santw1), greater synergy decreases the
chance of multi-drug resistance; the optimal drug interaction is
therefore maximal synergy (region below the black contour is
colored dark red), regardless of e . The magenta circle indicates
the combination of m and N0
tot corresponding to the original set of
model parameters.
Found at: doi:10.1371/journal.pcbi.1000796.s003 (0.10 MB TIF)
Figure S4 Partial antibiotic resistance weakens synergy ceiling
behavior. In the model we assume strong antibiotic resistance,
such that the antibiotic-resistant subpopulation feels the effect of
only a single drug; effectively, this makes the MIC of the drug to
which it is resistant infinite and produces the familiar synergy
ceiling, in which efficacy increases with e up to a critical level e 
and plateaus above it (blue line, Fig. 2; all lines have been shifted
on the vertical axis for clarity). As previously discussed (Fig. 3), this
plateau is due to the resistant subpopulation dying after the wild-
type when ewe . When we weaken the assumption of strong
resistance, however (MIC,‘), drug interactions still affect drug-
resistant mutants, even when such mutants are killed after the
wild-type. This results in efficacy increasing over all e, but
retaining its characteristic biphasic profile (red, green, orange
lines). This biphasic behavior is due to the stronger killing of the
wild-type than the resistant mutant, which persists even with only
partial resistance. While stronger resistance produces behavior
similar to the typical synergy ceiling (MIC increases 100-fold, red
line), weaker resistance (MIC increases 4-fold, orange line) yields a
still-biphasic curve, but one in which increases in e improve
efficacy substantially in all cases. The synergy ceiling behavior is
therefore most relevant in cases of strong antibiotic resistance.
Found at: doi:10.1371/journal.pcbi.1000796.s004 (0.08 MB TIF)
Table S1 Parameters used in this study.
Found at: doi:10.1371/journal.pcbi.1000796.s005 (0.03 MB
DOC)
Text S1
Found at: doi:10.1371/journal.pcbi.1000796.s006 (0.02 MB
DOC)
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